Review: Seneca Growth Capital VCT
Exclusive deal - ZERO initial charge
Apply online by 14 December and pay no initial charge – a saving of 5.5% on the full initial charge. This discount is only available through Wealth Club. You cannot get this deal anywhere else.
The tightening of the VCT rules in 2015 sent shockwaves through the VCT industry. But it also created opportunities for new entrants.
Take the team at Seneca Partners. They have never managed a VCT before, but currently manage more than £50 million of EIS growth capital. During the last six years they have participated in more than 70 investment rounds across 39 companies, often investing alongside the likes of Octopus, Northern, Mobeus and Baronsmead. In other words, Seneca has spent years making the kind of growth capital investment VCTs are required to make under the new rules.
It is therefore little surprise that the team has now decided to put that experience to use and launch a new VCT offering, the Seneca Growth Capital VCT.
Potential for dividends in the early years
Despite being new, it could potentially start paying dividends in the early years.
This is possible because rather than launching from scratch, Seneca partnered with the existing Hygea vct plc (now renamed Seneca Growth Capital VCT plc) and launched a new – and separate – B share class.
Crucially, this new share class will have access to distributable reserves on the company’s balance sheet. Seneca plans to use them to enable dividend payments for the first few years, until the investments held within the B shares mature and can be realised to help fund dividends. Please note dividends are variable and not guaranteed.
What kind of investments can be expected?
The VCT intends to broadly split its investments 50:50 between AIM-listed and unquoted companies.
It should benefit from the same strong regional deal flow as the EIS funds and mirror their investment process and strategy. It will target young but proven businesses ready to expand.
An example is SuperCarers, an online service that matches people in need of care with vetted, reliable, local carers. The business was originally backed by the founders of Innocent Drinks and the Chairman of Chelsea and Westminster Hospital.
Seneca invested £1.25 million through its EIS funds in March 2018. The funding round was led by Mobeus VCTs.Please note: this example illustrates the types of future investments. The VCT does not invest in SuperCarers.
A good EIS track record to date
During the 5 years to 31 March 2018, the Seneca Growth Capital EIS Fund and the Seneca EIS Portfolio Service have together delivered a combined average (unaudited) NAV growth rate of approximately 8.9% p.a. (an estimated 7.3% p.a. after fees andcharges). The figures include nine full and partial realisations and three write-offs. Past performance is not a guide to the future.
|Financial year ending 31 March|
|Annual growth rate||3%||29%||0%||10%||3%||9%|
Risks – important
This, like all investments available through Wealth Club, is only for experienced investors happy to make their own investment decisions without advice.
VCTs are high-risk so should only form part of a balanced portfolio and you should not invest money you cannot afford to lose. They also tend to be illiquid and hard to sell and value. Before you invest, please carefully read the Risks and Commitments and the offer documents to ensure you fully understand the risks.
Tax rules can change and benefits depend on circumstances.
VCTs can now only invest new money in growth capital deals. Management buyouts/replacement capital deals and investments in mature companies are no longer permitted. This results in considerably higher risks.
What to consider next
Please visit the offer page using the link below to download the provider documents, read more (including risks and charges) and apply online.
Wealth Club aims to make it easier for experienced investors to find information on – and apply for – tax-efficient investments. You should base your investment decision on the provider's documents and ensure you have read and fully understand them before investing. This review is a marketing communication. It is not advice or a personal or research recommendation to buy the investment mentioned. It does not satisfy legal requirements promoting investment research independence and is thus not subject to prohibitions on dealing ahead of its dissemination.
Read more and apply online
Read more about this offer, including the risks; download all the documents and apply online in minutes.Go to offer page